Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.82 |
| ▸ | ADK | P55263 | 3/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.45 |
| ▸ | MTOR | P42345 | 3/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765844 | 0.93 | NOS1 (0.82) | NOS1ADKPIK3CDPIK3CGGAK | |
| SCHEMBL3762228 | 0.91 | NOS1 (0.95) | NOS1ADKPIK3CDPIK3CGGAK | |
| SCHEMBL4450556 | 0.91 | NOS1 (0.79) | NOS1ADKPIK3CDPIK3CGGAK | |
| SCHEMBL5508882 | 0.91 | NOS1 (0.79) | NOS1ADKPIK3CDPIK3CGGAK | |
| SCHEMBL5317835 | 0.90 | NOS1 (1.00) | NOS1ADKPIK3CDPIK3CGPIK3CA | |
| SCHEMBL3752607 | 0.90 | NOS1 (0.74) | NOS1ADKPIK3CDPIK3CGGAK | |
| SCHEMBL3765481 | 0.89 | NOS1 (0.80) | NOS1ADKPIK3CDPIK3CGGAK | |
| Water SCHEMBL6491267 | 0.89 | NOS1 (0.98) | NOS1ADKPIK3CDPIK3CGPIK3CA | |
| Hydrochloric Acid SCHEMBL6494704 | 0.89 | NOS1 (0.76) | NOS1ADKPIK3CDPIK3CGGAK | |
| SCHEMBL3765371 | 0.88 | NOS1 (0.75) | NOS1ADKPIK3CDPIK3CGGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144736-B2 | Substituted pteridines useful for the treatment and prevention of viral infections | GILEAD SCIENCES, INC. (US) | 2018-12-04 | — | — | US | claimed |
| US-7501513-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2009-03-10 | — | — | US | claimed |
| EP-1658081-B1 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA IP NV (BE) | 2007-10-24 | — | — | EP | claimed |
| EP-1663244-B1 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | claimed |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | 4 AZA BIOSCIENCE NV (BE) | 2007-01-04 | — | — | US | claimed |
| US-20060287314-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2006-12-21 | — | — | US | claimed |
| US-20190152974-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2019-05-23 | — | — | US | disclosed |
| US-7501513-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2009-03-10 | — | — | US | disclosed |
| EP-1658081-B1 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA IP NV (BE) | 2007-10-24 | — | — | EP | disclosed |
| EP-1663244-B1 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | 4 AZA BIOSCIENCE NV (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20060287314-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2006-12-21 | — | — | US | disclosed |
| EP-1663244-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-ALPHA-RELATED DISEASES. | 4 AZA Bioscience nv (BE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1658081-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005025574-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. | 4 AZA BIOSCIENCE NV (BE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005021003-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152974-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HCCS, DPYD, HAVCR2 | NOS1 2154/4885ADK 2266/4885PIK3CD 2324/4885 |
| US-10144736-B2 | Substituted pteridines useful for the treatment and prevention of viral infections | HCCS, DPYD, HAVCR2 | NOS1 2154/4885ADK 2266/4885PIK3CD 2324/4885 |
| US-20060287314-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, NFATC1, MALT1 | NOS1 118/4885ADK 2848/4885PIK3CD 872/4885 |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | TNF, TNFRSF1A, TLR4 | NOS1 47/4885ADK 1148/4885PIK3CD 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.